Generic Medicine Info
Indications and Dosage
Dermal necrosis associated with norepinephrine IV infusion
Adult: Prevention: 10 mg is added to each liter of solution containing norepinephrine. Treatment of extravasation: Inject 5-10 mg in 10 ml normal saline into the affected area.
Child: Treatment: Infiltrate area with 0.1 to 0.2 mg/kg (max 10 mg).

Hypertension in phaeochromocytoma
Adult: 2-5 mg. Repeat if necessary. Monitor BP.
Child: 1 mg IM/IV 1-2 hr before surgery. During surgery, 1 mg IV as indicated.

Diagnosis of pheochromocytoma
Adult: 2.5-5 mg IM/IV.
Child: 1 mg IV or 3 mg IM.
Renal impairment, coronary or cerebral arteriosclerosis, concurrent use with phosphodiesterase-5 (PDE-5) inhibitors including sildenafil (>25 mg), tadalafil, or vardenafil.
Special Precautions
Tachycardia or history of cardiac arrhythmias; gastritis or peptic ulcer disease; pregnancy and lactation. Discontinue if symptoms of angina occur or worsen.
Adverse Reactions
Orthostatic hypotension, tachycardia, flushing, sweating, feelings of apprehension, anginal pain, arrhythmias, nausea, vomiting, diarrhoea, weakness, dizziness, nasal congestion.
Potentially Fatal: MI, cerebrovascular spasm or occlusion.
IM/IV/Parenteral: C
Hypoglycaemia; severe hypotension, tachycardia, vomiting, dizziness. If fluid replacement is inadequate to treat hypotension, only alpha-adrenergic vasopressors such as norepinephrine should be used. Mixed agents such as epinephrine may cause more hypotension.
Drug Interactions
Epinephrine, ephedrine: effects may be decreased; ethanol: increased toxicity (disulfiram reaction).
Potentially Fatal: Additive BP-lowering effects with sildenafil, tadalafil or vardenafil.
Description: Phentolamine is a reversible (competitive) and non-selective alpha-adrenergic receptor blocker, producing brief antagonism of circulating epinephrine and norepinephrine to reduce hypertension caused by alpha effects of these catecholamines. It has direct action on vascular smooth muscle; and has positive inotropic and chronotropic effects on the heart as well.
Onset: IM: 15-20 min; IV: immediate.
Duration: IM: 30-45 min; IV: 15-30 min.
Metabolism: Hepatic.
Excretion: Metabolism: Hepatic. Via urine (10% as unchanged drug); half-life elimination: 19 min.
The reconstituted solution should be used upon preparation and should not be stored. Store unopened vials at controlled room temperature (59-86°F).
Disclaimer: This information is independently developed by MIMS based on Phentolamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in